临床阶段的CK2特异性抑制剂CX-4945对慢性淋巴细胞白血病的活性。 - Suppr

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.

作者信息

Martins L R, Lúcio P, Melão A, Antunes I, Cardoso B A, Stansfield R, Bertilaccio M T S, Ghia P, Drygin D, Silva M G, Barata J T

机构信息

Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal.

CEDOC, Faculdade de Ciências Médicas, FCM, Universidade Nova de Lisboa and Instituto Português de Oncologia, Lisbon, Portugal.

出版信息

Leukemia. 2014 Jan;28(1):179-82. doi: 10.1038/leu.2013.232. Epub 2013 Aug 8.

DOI:10.1038/leu.2013.232

PMID:23925046

Abstract

摘要

相似文献

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.

Leukemia. 2014 Jan;28(1):179-82. doi: 10.1038/leu.2013.232. Epub 2013 Aug 8.

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.

Leukemia. 2013 Oct;27(10):2094-6. doi: 10.1038/leu.2013.228. Epub 2013 Jul 31.

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.

Mol Cell Biochem. 2011 Oct;356(1-2):37-43. doi: 10.1007/s11010-011-0956-5. Epub 2011 Jul 14.

Chronic lymphocytic leukemia.

Exp Oncol. 2012 Dec;34(4):378-80.

Chronic lymphocytic leukemia: where are we and where are we going?

Expert Opin Pharmacother. 2012 Aug;13(12):1675-7. doi: 10.1517/14656566.2012.703653. Epub 2012 Jul 7.

CX-5461 inhibits RNA Pol I in blood cancers.

Cancer Discov. 2014 Dec;4(12):OF5. doi: 10.1158/2159-8290.CD-NB2014-154. Epub 2014 Oct 9.

Fludarabine approved for use in chronic lymphocytic leukemia.

Oncology (Williston Park). 1991 Jun;5(6):20.

Optimizing drug dosing for the treatment of chronic lymphocytic leukemia.

Clin Adv Hematol Oncol. 2019 Jun;17(6):330-331.

The evolving role of chemoimmunotherapy in chronic lymphocytic leukemia.

Clin Adv Hematol Oncol. 2016 Oct;14(10):756-758.

B-cell receptor inhibitors in chronic lymphocytic leukemia.

Clin Adv Hematol Oncol. 2013 Jun;11(6):362-4.

引用本文的文献

Casein Kinase 2α Ablation Confers Protection Against Metabolic Dysfunction-Associated Steatotic Liver Disease: Role of FUN14 Domain Containing 1-Dependent Regulation of Mitophagy and Ferroptosis.

MedComm (2020). 2025 Jul 11;6(7):e70277. doi: 10.1002/mco2.70277. eCollection 2025 Jul.

Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy.

Front Immunol. 2024 May 14;15:1393485. doi: 10.3389/fimmu.2024.1393485. eCollection 2024.

In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia.

Sci Rep. 2022 Oct 21;12(1):17648. doi: 10.1038/s41598-022-21546-0.

The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review.

J Dev Biol. 2022 Jul 27;10(3):31. doi: 10.3390/jdb10030031.

Casein Kinase 2 Signaling in White Matter Stroke.

Front Mol Biosci. 2022 Jul 13;9:908521. doi: 10.3389/fmolb.2022.908521. eCollection 2022.

Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.

Int J Mol Sci. 2022 Jun 6;23(11):6353. doi: 10.3390/ijms23116353.

The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target.

Oncogene. 2022 Apr;41(14):2003-2011. doi: 10.1038/s41388-022-02245-6. Epub 2022 Feb 26.

4,5,7-Trisubstituted indeno[1,2-b]indole inhibits CK2 activity in tumor cells equivalent to CX-4945 and shows strong anti-migratory effects.

FEBS Open Bio. 2022 Feb;12(2):394-411. doi: 10.1002/2211-5463.13346. Epub 2021 Dec 18.

Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy.

Commun Biol. 2021 May 28;4(1):638. doi: 10.1038/s42003-021-02136-8.

Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Signal Transduct Target Ther. 2021 May 17;6(1):183. doi: 10.1038/s41392-021-00567-7.

本文引用的文献

Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.

Leukemia. 2012 Jun;26(6):1174-9. doi: 10.1038/leu.2011.385. Epub 2012 Jan 13.

Update on therapy of chronic lymphocytic leukemia.

J Clin Oncol. 2011 Feb 10;29(5):544-50. doi: 10.1200/JCO.2010.32.3865. Epub 2011 Jan 10.

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Cancer Res. 2010 Dec 15;70(24):10288-98. doi: 10.1158/0008-5472.CAN-10-1893.

The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival.

Adv Enzyme Regul. 2011;51(1):37-49. doi: 10.1016/j.advenzreg.2010.09.012. Epub 2010 Oct 28.

Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.

Blood. 2010 Oct 14;116(15):2724-31. doi: 10.1182/blood-2010-04-277947. Epub 2010 Jul 21.

Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.

Blood. 2010 Oct 7;116(14):2513-21. doi: 10.1182/blood-2009-10-248054. Epub 2010 Jun 24.

Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options.

Leuk Lymphoma. 2010 Jul;51(7):1188-99. doi: 10.3109/10428194.2010.486089.

Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.

Leukemia. 2009 Mar;23(3):457-66. doi: 10.1038/leu.2008.322. Epub 2008 Nov 6.

The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.

Leukemia. 2007 Jan;21(1):110-20. doi: 10.1038/sj.leu.2404417. Epub 2006 Oct 5.

Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL.

Leukemia. 2006 Mar;20(3):514-20. doi: 10.1038/sj.leu.2404113.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献